



MOMENTA

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast

February 7, 2018

CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2017 before the U.S. financial markets open on Wednesday, February 21, 2018.

Management will host a conference call on that date at 10:00 a.m. EST to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 6799797. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:

Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com

[Primary Logo](#)

Source: Momenta Pharmaceuticals, Inc.